Clinical Lymphoma, Myeloma and Leukemia

Published by: Elsevier Inc.  

People

  1. Usmani
    Usmani
  2. Giralt
    Giralt
  3. Lesokhin
    Lesokhin
  4. Landau
    Landau
  5. Hassoun
    Hassoun
  6. Korde
    Korde
  7. Mailankody
    Mailankody
  8. Hultcrantz
    Hultcrantz
  9. Mauro
    Mauro
  10. Shah
    Shah

Groups

  1. Hematologic Malignancies, Division of (327)
  2. Department of Medicine (324)
  3. Center for Hematologic Malignancies (302)
  4. Adult Leukemia (116)
  5. Myeloma (96)
  6. Survivorship Research (85)
  7. Hematologic Malignancies Research (84)
  8. Bone Marrow Transplant (77)
  9. Sloan Kettering Institute Postdocs (68)
  10. Lymphoma (62)
Search Within
Formats
  1. Meeting Abstract (311)
  2. Journal Article (72)
  3. Review (8)
  4. Conference Paper (1)
  5. Editorial (1)
  6. Guidelines (1)
  7. Research Letter (1)
Groups
  1. Hematologic Malignancies, Division of (327)
  2. Department of Medicine (324)
  3. Center for Hematologic Malignancies (302)
  4. Adult Leukemia (116)
  5. Myeloma (96)
  6. Survivorship Research (85)

More Groups

People
  1. Saad Usmani (79)
  2. Sergio Giralt (60)
  3. Alexander Lesokhin (57)
  4. Heather Landau (53)
  5. Hani Hassoun (51)
  6. Malin Hultcrantz (50)

More People

Years
  1. 2025 (2)
  2. 2024 (44)
  3. 2023 (79)
  4. 2022 (64)
  5. 2021 (40)
  6. 2020 (29)

More Years

Publishers
  1. Elsevier Inc. (395)

Results (395)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Addition of elotuzumab to backbone treatment regimens for multiple myeloma: An updated meta-analysis of randomized clinical trials
    Journal Article

    Costa, B. A.; Costa, T. A.; Chagas, G. C. L.; Mouhieddine, T. H.; Richter, J.; Usmani, S. Z.; Mailankody, S.; Rajeeve, S.; Hashmi, H.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Influence of obesity on the efficacy and toxicity of patients undergoing autologous hematopoietic cell transplantation for lymphoma
    Journal Article

    Lin, A.; Pearl, N.; Flynn, J.; Devlin, S.; Dahi, P.; Perales, M. A.; Scordo, M.; Shah, G. L.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens (SRs) in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 sub-analysis of black patients
    Meeting Abstract

    Patel, K. K.; Rodríguez-Otero, P.; Nooka, A. K.; Callander, N. S.; Solomon, S. R.; Baz, R.; Sborov, D. W.; Gergis, U.; Badros, A. Z.; Giralt, S. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Pelabresib plus ruxolitinib combination therapy in jak inhibitor-naïve patients with myelofibrosis in the phase 3 MANIFEST-2 study: Preliminary evidence of bone marrow recovery
    Meeting Abstract

    Mascarenhas, J.; Rampal, R. K.; Vannucchi, A. M.; Gupta, V.; Oh, S. T.; Kuykendall, A. T.; Mesa, R.; Kiladjian, J. J.; Talpaz, M.; Kremyanskaya, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Dose-optimization study of 3 starting doses of ponatinib: Long-term results from the OPTIC trial
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
    Meeting Abstract

    Erba, H. P.; Oluwole, O. O.; Bixby, D.; Rampal, R. K.; Fathi, A. T.; Paliwal, P.; Jin, J.; Inoue, A.; Daver, N.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV): An analysis from the prospective observational study of patients with polycythemia vera in US clinical practices (REVEAL)
    Meeting Abstract

    Grunwald, M. R.; Zwicker, J. I.; Gerds, A. T.; Burke, J. M.; Xue, Z.; Crowgey, E. L.; Carl, J.; Feldman, P.; Braunstein, E. M.; Oh, S. T.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory CLL/SLL: Results from BTK-naïve cohort in the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Eyre, T. A.; Lech-Maranda, E.; Roeker, L. E.; Patel, M.; Fukuhara, N.; Woyach, J. A.; Brown, J. R.; Patel, K.; Tam, C. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Characteristics of patients and management of ocular adverse events after treatment with belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma (RRMM): A real-world study in Europe
    Meeting Abstract

    Cavo, M.; Delforge, M.; Dimopoulos, M.; Escalante-Barrigon, F.; Hultcrantz, M.; Kleinman, D.; Lee, H.; Vij, R.; Greil, R.; Melchardt, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Daratumumab + bortezomib/lenalidomide/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: Results of the phase 3 CEPHEUS study
    Meeting Abstract

    Usmani, S. Z.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Pour, L.; Marti, J.; Basu, S.; Cohen, Y. C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save

    • Clinical Lymphoma, Myeloma and Leukemia – authorized name for:

    Name ISSN / ISBN Publisher
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cancer Media Group
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cig Media Group, Lp
    Clinical Lymphoma, Myeloma & Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 2152-2650 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 1368-8375 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 152-2650 2021
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Ltd
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2022
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2023
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2024
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Author(s)
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Authors
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2021
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Unknown (2152-2650) 2152-2650 Unknown